Pre-conditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy

Authors
Christianne Groeneveldt, Priscilla Kinderman, Diana J. M. van den Wollenberg, Ruben L. van den Oever, Jim Middelburg, Dana A. M. Mustafa, Rob C. Hoeben, Sjoerd H. van der Burg, Thorwald van Hall* and Nadine van Montfoort†

*These authors contributed equally to this work

In short
- Oncolytic reovirus converts the immune-silent TME into an inflamed site by inducing a local IFN response and strong T cell influx.
- Pre-conditioning with replicating reovirus is required to induce tumor regressions upon CD3-bispecific antibody (CD3-bsAb) therapy.
- Synergy of reovirus and CD3-bsAb therapy is not restricted to the injected tumor but also observed in a distant tumor and after systemic reovirus administration.